Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25029791 | 0.88 | MTNR1A (0.40) | MTNR1AMTNR1BHTR2BHTR2AMPO | |
| SCHEMBL25988580 | 0.85 | MTNR1A (0.34) | MTNR1AMTNR1BHTR2B | |
| SCHEMBL25029964 | 0.80 | MPO (0.46) | MTNR1AMTNR1BHTR2BHTR2AMPO | |
| SCHEMBL25987650 | 0.78 | HTR2A (0.50) | HTR2BHTR2AMPOKDM4ENPSR1 | |
| SCHEMBL25030244 | 0.78 | MTNR1A (0.43) | MTNR1AMTNR1BHTR2AMPONQO2 | |
| SCHEMBL25028270 | 0.78 | HTR2B (0.38) | MTNR1AMTNR1BHTR2BHTR2AMPO | |
| SCHEMBL25029895 | 0.73 | MTNR1A (0.46) | MTNR1AMTNR1BHTR2BHTR2AMPO | |
| SCHEMBL23069143 | 0.73 | MTNR1A (0.64) | MTNR1AMTNR1BHTR2BHTR2AMPO | |
| SCHEMBL29967548 | 0.73 | MTNR1A (0.64) | MTNR1AMTNR1BHTR2BHTR2AMPO | |
| SCHEMBL25987632 | 0.71 | HTR2A (0.38) | MTNR1AMTNR1BHTR2ANQO2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780807-B2 | Benzoselenophene, benzothiophene, and benzofuran analogs and methods of modulating the serotonin 5-HT2C receptor | Kuleon, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780807-B2 | Benzoselenophene, benzothiophene, and benzofuran analogs and methods of modulating the serotonin 5-HT2C receptor | Kuleon, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | Kuleon, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023018864-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780807-B2 | Benzoselenophene, benzothiophene, and benzofuran analogs and methods of modulating the serotonin 5-HT2C receptor | HTR2C, HTR2A, HTR3C | MTNR1A 124/4885MTNR1B 156/4885HTR2B 4/4885 |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | HTR2C, HTR2A, HTR3B | MTNR1A 293/4885MTNR1B 222/4885HTR2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.